mobic and Spinal-Diseases

Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Female; Humans; Male; Meloxicam; Spinal Diseases; Thiazines; Thiazoles

The aim of this study was to evaluate the efficacy and tolerability of meloxicam compared with diclofenac in patients with osteoarthritis of the lumbar spine.. 229 patients with radiologically confirmed osteoarthritis of the lumbar spine.. Once-daily meloxicam 7.5 mg tablet or diclofenac 100 mg slow release tablet. Efficacy and tolerability parameters were assessed at baseline and after 3, 7 and 14 days of treatment.. The two drugs had equal short-term efficacy, with pain on motion of lumbar spine significantly (p<0.05) decreased at Day 3. Secondary efficacy variables were also significantly improved at Days 3, 7 and 14. There were no statistically significant differences between the two drugs, although the global tolerability of meloxicam was significantly better than for diclofenac, as assessed by the investigators (p = 0.0072) and the patients (p = 0.049).. Meloxicam and diclofenac were equivalent in relieving the acute pain associated with osteoarthritis of the lumbar spine. However, meloxicam was much better tolerated.

Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lumbar Vertebrae; Male; Meloxicam; Middle Aged; Osteoarthritis; Spinal Diseases; Thiazines; Thiazoles

In regard to therapeutic effect of different medications used in dorsopathy treatment, non-steroid anti-inflammatory drugs rank first. Compounds selectively blocking COX-2 received special attention due to their minimal impact on COX-1 that provides good anti-inflammatory and analgesic effect with simultaneous dramatic reduction of ulcerogenic activity. One of the first drugs with such an action is Movalis (meloxicam). Thirty patients were divided into 2 groups, the first including 22 patients with vertebral diseases and musculotonic syndromes; patients of the second group (8) had a pain syndrome caused by disk herniation. During the first 3 days Movalis was administered in the form of injections (15 mg/day) and in the same doses in tablets for the following 20 days. After the treatment course, complete arrest of pain syndrome was observed in 33.3% patients, significant improvement--in 53.3% and insignificant effect--in 13.3%. Patients with reflex pain and musculotonic syndromes had a good analgesic effect after 3-day course of intramuscular injections, with the effect being mostly expressed in 8-10 days. Patients with diskogenic compressive radicular syndrome demonstrated a stable analgesic effect after a week of Movalis intake in tablet form. Movalis is well tolerated; side effects have occurred in 10 patients but they were minimal and did not lead to the change of medication dose or additional therapy.

Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Cyclooxygenase Inhibitors; Female; Humans; Injections, Intramuscular; Intervertebral Disc Displacement; Low Back Pain; Male; Meloxicam; Middle Aged; Osteochondritis; Pain Measurement; Spinal Diseases; Spondylarthropathies; Tablets; Thiazines; Thiazoles; Time Factors; Treatment Outcome

To assess the response to nonsteroid antiinflammatory drug movalis in LBP syndrome.. Movalis was given in daily dose 15 mg for 7 days, then 7.5 mg daily for 14 days to 22 patients with LBS aged 34-56 years. All the patients had lumbosacral intervertebral osteochondrosis complicated with secondary radiculitis or myofascial syndrome.. Movalis noticeably relieved pain syndrome. At the end of the treatment two-thirds of the patients were able to move. Tolerance of the drug was good, satisfactory and bad in 10, 7 and 1 patients, respectively.. Movalis is effective in LBP syndrome.

Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Disability Evaluation; Female; Humans; Isoenzymes; Low Back Pain; Male; Meloxicam; Middle Aged; Osteochondritis; Pain Measurement; Radiculopathy; Spinal Diseases; Thiazines; Thiazoles; Treatment Outcome